Abigail Brooks

The restrictive strategy led to fewer cholecystectomies without increasing complications but did not improve pain-free outcomes versus usual care for symptomatic cholelithiasis.

In an interview with NBC News, the former president defended himself over abortion rights and said either the government or insurance companies will pay for IVF if he's elected.

Data for more than 2 million blood donors in Canada provides insight into HCV antibody positivity trends in this notoriously low-risk patient population.

The HCPLive August gastroenterology month in review spotlights expansions in gastrointestinal treatment and screening access as well as the newest edition of Qazi Corner.

Rizk discusses the recent FDA accelerated approval of iptacopan (Fabhalta) and reflects on the significance of other therapeutic developments in IgAN.

This August 2024 month in review spotlights HCPLive's top coverage of hepatic pipeline news and recent research in liver disease, HCV, and more.

The Delphi survey collected opinions from members of the European Alpha-1 Research Collaboration to guide the diagnosis, treatment, and management of severe AATD.

Findings support the use of FIB-4's low cut-off for ruling out severe fibrosis and cirrhosis as well as the use of Forns index's high cut-off for significant fibrosis in chronic HCV.

Barratt reflects on recent therapeutic developments in IgAN, the most recent being the full FDA approval of sparsentan (Filspari), and the importance of preventing kidney failure.

People with chronic liver disease were more likely to experience healthcare barriers and require recurrent acute care compared to those with COPD and/or CVD.